Patents by Inventor Karl Guegler

Karl Guegler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240218466
    Abstract: A stand-alone molecular diagnostic test device includes a housing, a reverse transcription module, an amplification module, and a detection module. The reverse transcription module is configured to heat a biological sample to produce a target cDNA molecule associated with an RNA virus thereby producing an amplification solution. The amplification module defines a reaction volume configured to receive the amplification solution and amplify the target cDNA molecule within the amplification solution to produce an output. The detection module is configured to receive the output from the amplification module and includes one or more probes specific to a polynucleotide sequence of the RNA virus. The one or more probes is designed to facilitate production of a signal indicating the presence of the RNA virus in the biological sample.
    Type: Application
    Filed: March 23, 2021
    Publication date: July 4, 2024
    Inventors: Mackenzie HUNT, Karl GUEGLER, David SWENSON, Shaunak ROY, Paul DENTINGER, Brian CIOPYK, Samira DASWANI, Gary SCHOOLNIK, Teresa ABRAHAM
  • Patent number: 11952636
    Abstract: The disclosure relates generally to molecular diagnostic devices configured to amplifying a single nucleotide polymorphism (SNP) locus and discriminate between two or more allelic variants of the SNP, indicating presence or absence of a target allele. In some embodiments, the molecular diagnostic devices are capable of detecting, at point-of-care, SNPs associated with resistance or susceptibility to antibiotic treatment of organism infections. In other aspects, the disclosure provides methods of treatment for disease or disorders (e.g. organism infections) where treatment is guided by presence or absence of an allele at a SNP locus as determined by such molecular diagnostic devices.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: April 9, 2024
    Assignee: Visby Medical, Inc.
    Inventors: Brian Ciopyk, Paul Dentinger, Teresa Abraham, Brandon Ma, Kamal Kajouke, Mackenzie Hunt, Austin Phung, Karl Guegler, David Swenson, Anna H. Postlethwaite
  • Publication number: 20220112550
    Abstract: The invention is directed to methods for analyzing polymers comprising linear chains of at least two types of monomers, such as polynucleotides, including DNA, RNA, and the like, using nanopores and optical detection. In some embodiments, as few as two different kinds of nucleotide are labeled with different optical labels that generate distinguishable optical signals for the selected kinds of nucleotide in both sense strands and antisense strands of target polynucleotides. Labeled strands are translocated through nanopores where nucleotides of the strands are constrained to pass sequentially through an optical detection region where their labels generate a sequence of optical signals making up an optical signature. In some embodiments, information from optical signatures from both sense and antisense strands are combined to determine complete nucleotide sequences of target polynucleotides.
    Type: Application
    Filed: August 3, 2021
    Publication date: April 14, 2022
    Applicant: Quantapore, Inc.
    Inventors: Karl GUEGLER, Jan F. SIMONS, Stephen C. MACEVICZ
  • Publication number: 20220106629
    Abstract: The invention provides methods for analyzing polynucleotides using nanopores that allow passage of single stranded polynucleotides but not double stranded polynucleotides. In accordance with some embodiments, a double-stranded product is produced that comprises a labeled strand with a single stranded tail or overhang. The double stranded product is exposed to one or more nanopores in the presence of an electric field across the one or more nanopores such that the single stranded tail may be captured and the labeled strand translocated by unzipping from the double stranded product. The ionic composition of the reaction mixture and electric field strength are selected so that nucleotides translocate a nanopore at a rate of less than 1000 nucleotides per second.
    Type: Application
    Filed: July 2, 2021
    Publication date: April 7, 2022
    Applicant: Quantapore, Inc.
    Inventors: Tao HONG, Karl GUEGLER, Jan F. SIMONS
  • Publication number: 20190112649
    Abstract: The invention is directed to methods for analyzing polymers comprising linear chains of at least two types of monomers, such as polynucleotides, including DNA, RNA, and the like, using nanopores and optical detection. In some embodiments, as few as two different kinds of nucleotide are labeled with different optical labels that generate distinguishable optical signals for the selected kinds of nucleotide in both sense strands and antisense strands of target polynucleotides. Labeled strands are translocated through nanopores where nucleotides of the strands are constrained to pass sequentially through an optical detection region where their labels generate a sequence of optical signals making up an optical signature. In some embodiments, information from optical signatures from both sense and antisense strands are combined to determine complete nucleotide sequences of target polynucleotides.
    Type: Application
    Filed: May 4, 2017
    Publication date: April 18, 2019
    Applicant: Quantapore, Inc.
    Inventors: Karl GUEGLER, Jan F. SIMONS, Stephen C. MACEVICZ
  • Publication number: 20190078145
    Abstract: The invention provides methods for analyzing polynucleotides using nanopores that allow passage of single stranded polynucleotides but not double stranded polynucleotides. In accordance with some embodiments, a double-stranded product is produced that comprises a labeled strand with a single stranded tail or overhang. The double stranded product is exposed to one or more nanopores in the presence of an electric field across the one or more nanopores such that the single stranded tail may be captured and the labeled strand translocated by unzipping from the double stranded product. The ionic composition of the reaction mixture and electric field strength are selected so that nucleotides translocate a nanopore at a rate of less than 1000 nucleotides per second.
    Type: Application
    Filed: November 28, 2016
    Publication date: March 14, 2019
    Applicant: QUANTAPORE, INC.
    Inventors: Tao HONG, Karl GUEGLER, Jan F. SIMONS
  • Publication number: 20180237843
    Abstract: Disclosed are methods and compositions for determining the average length or abundance of a first target nucleic by calculating the abundance of a first target nucleic acid (T) relative to the average abundance (S) of a second and a third target nucleic acid, in a single well using a separate detection label for each target nucleic acid. In various aspects, the first target nucleic acid is a telomere. In exemplary aspects, the disclosed methods and compositions can be used to determine the average telomere length in a biological sample. The average telomere length determined using the disclosed methods and compositions can be correlated to a variety of clinically important conditions and indices. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: April 16, 2018
    Publication date: August 23, 2018
    Inventors: Calvin Harley, Jue Lin, Karl Guegler
  • Patent number: 9944978
    Abstract: Disclosed are methods and compositions for determining the average length or abundance of a first target nucleic by calculating the abundance of a first target nucleic acid (T) relative to the average abundance (S) of a second and a third target nucleic acid, in a single well using a separate detection label for each target nucleic acid. In various aspects, the first target nucleic acid is a telomere. In exemplary aspects, the disclosed methods and compositions can be used to determine the average telomere length in a biological sample. The average telomere length determined using the disclosed methods and compositions can be correlated to a variety of clinically important conditions and indices. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: April 17, 2018
    Assignee: TELOMERE DIAGNOSTICS, INC.
    Inventors: Calvin Harley, Jue Lin, Karl Guegler
  • Publication number: 20170233791
    Abstract: Provided herein are methods and compositions for performing PCR with primers with blocked 3?-ends that are unblocked when these primers anneal to the template. The multiplexed PCR can be used as real-time qPCR, for end-point detection or as enrichment method for next generation sequencing (NGS). Also described herein are methods and compositions to improve sensitivity of mutation-specific PCR when targeting closely-spaced mutations.
    Type: Application
    Filed: December 19, 2016
    Publication date: August 17, 2017
    Inventors: Eugene Spier, Karl Guegler
  • Patent number: 9523121
    Abstract: Provided herein are methods and compositions for performing PCR with primers with blocked 3?-ends that are unblocked when these primers anneal to the template. The multiplexed PCR can be used as real-time qPCR, for end-point detection or as enrichment method for next generation sequencing (NGS). Also described herein are methods and compositions to improve sensitivity of mutation-specific PCR when targeting closely-spaced mutations.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: December 20, 2016
    Assignee: Uni Taq Bio
    Inventors: Eugene Spier, Karl Guegler
  • Patent number: 9518296
    Abstract: The present teachings provide methods, compositions, and kits for detecting the presence of protein aggregates. In some embodiments, the protein aggregate is treated with a labeled precursor, and the labeled precursor is incorporated into the protein aggregate to form a labeled protein aggregate. The labeled protein aggregate is then measured, thus detecting the presence of the protein aggregate. In some embodiments, the labeled protein aggregate is detected by interaction of labeled precursors, for example by a proximity ligation assay.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: December 13, 2016
    Assignee: APPLIED BIOSYSTEMS LLC
    Inventors: David Ruff, Mark Shannon, Kenneth Livak, Karl Guegler, Kevin Hennessy
  • Publication number: 20160186250
    Abstract: Disclosed are methods and compositions for determining the average length or abundance of a first target nucleic by calculating the abundance of a first target nucleic acid (T) relative to the average abundance (S) of a second and a third target nucleic acid, in a single well using a separate detection label for each target nucleic acid. In various aspects, the first target nucleic acid is a telomere. In exemplary aspects, the disclosed methods and compositions can be used to determine the average telomere length in a biological sample. The average telomere length determined using the disclosed methods and compositions can be correlated to a variety of clinically important conditions and indices. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: June 22, 2015
    Publication date: June 30, 2016
    Inventors: Calvin Harley, Jue Lin, Karl Guegler
  • Publication number: 20140329245
    Abstract: Provided herein are methods and compositions for performing PCR with primers with blocked 3?-ends that are unblocked when these primers anneal to the template. The multiplexed PCR can be used as real-time qPCR, for end-point detection or as enrichment method for next generation sequencing (NGS). Also described herein are methods and compositions to improve sensitivity of mutation-specific PCR when targeting closely-spaced mutations.
    Type: Application
    Filed: January 13, 2014
    Publication date: November 6, 2014
    Applicant: UniTaq Bio
    Inventors: Eugene Spier, Karl Guegler
  • Publication number: 20140134624
    Abstract: The present teachings provide methods, compositions, and kits for detecting the presence of protein aggregates. In some embodiments, the protein aggregate is treated with a labeled precursor, and the labeled precursor is incorporated into the protein aggregate to form a labeled protein aggregate. The labeled protein aggregate is then measured, thus detecting the presence of the protein aggregate. In some embodiments, the labeled protein aggregate is detected by interaction of labeled precursors, for example by a proximity ligation assay.
    Type: Application
    Filed: August 23, 2013
    Publication date: May 15, 2014
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: David RUFF, Mark Shannon, Kenneth Livak, Karl Guegler, Kevin Hennessy
  • Publication number: 20080003604
    Abstract: The present teachings provide methods, compositions, and kits for detecting the presence of protein aggregates. In some embodiments, the protein aggregate is treated with a labeled precursor, and the labeled precursor is incorporated into the protein aggregate to form a labeled protein aggregate. The labeled protein aggregate is then measured, thus detecting the presence of the protein aggregate. In some embodiments, the labeled protein aggregate is detected by interaction of labeled precursors, for example by a proximity ligation assay.
    Type: Application
    Filed: May 2, 2007
    Publication date: January 3, 2008
    Applicant: Applera Corporation
    Inventors: David Ruff, Mark Shannon, Kenneth Livak, Karl Guegler, Kevin Hennessy
  • Publication number: 20070111226
    Abstract: The present teachings provide methods, compositions, and kits for quantifying target polynucleotides. In some embodiments, a reverse stem-loop ligation probe is ligated to the 3? end of a target polynucleotide, using a ligase that can ligate the 3? end of RNA to the 5? end of DNA using a DNA template, such as T4 DNA ligase. Following digestion to form an elongated target polynucleotide with a liberated end, a reverse transcription reaction can be performed, followed by a PCR. In some embodiments, the methods of the present teachings can discriminate between polymorphic polynucleoitides that vary by as little as one nucleotide.
    Type: Application
    Filed: August 24, 2006
    Publication date: May 17, 2007
    Applicant: APPLERA CORPORATION
    Inventors: Ruoying Tan, Caifu Chen, Karl Guegler
  • Publication number: 20070105171
    Abstract: The invention provides human protease molecules (HUPM) and polynucleotides which identify and encode HUPM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HUPM.
    Type: Application
    Filed: October 2, 2006
    Publication date: May 10, 2007
    Applicants: Incyte Pharmaceuticals, Inc., Genentech, Inc.
    Inventors: Olga Bandman, Jennifer Hillman, Henry Yue, Karl Guegler, Neil Corley, Y. Tang, Purvi Shah
  • Publication number: 20070054312
    Abstract: The invention provides human transmembrane proteins (HTMPN) and polynucleotides which identify and encode HTMPN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HTMPN.
    Type: Application
    Filed: November 8, 2006
    Publication date: March 8, 2007
    Inventors: Y. Tang, Preeti Lal, Jennifer Hillman, Henry Yue, Karl Guegler, Neil Corley, Olga Bandman, Chandra Patterson, Gina Gorgone, Matthew Kaser, Mariah Baughn, Janice Au-Young
  • Publication number: 20060281902
    Abstract: The invention provides a human signal peptide-containing proteins (SIGP) and polynucleotides which identify and encode SIGP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of SIGP.
    Type: Application
    Filed: March 23, 2006
    Publication date: December 14, 2006
    Inventors: Preeti Lal, Jennifer Hillman, Neil Corley, Karl Guegler, Mariah Baughn, Susan Sather, Purvi Shah
  • Publication number: 20060246486
    Abstract: The invention provides a human signal peptide-containing proteins (SIGP) and polynucleotides which identify and encode SIGP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of SIGP.
    Type: Application
    Filed: March 23, 2006
    Publication date: November 2, 2006
    Inventors: Preeti Lal, Jennifer Hillman, Neil Corley, Karl Guegler, Mariah Baughn, Susan Sather, Purvi Shah